Log in

Relevant bibliographies by topics / Insuline – Administration

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Insuline – Administration'

Author: Grafiati

Published: 4 June 2021

Last updated: 23 November 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Insuline – Administration.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Insuline – Administration"

1

CARLBORG., J. TILLGREN et UNO. "Le traitement diabétique par insuline de dépôt (I.P.Z.) et par administration d'insuline (I. O.)tràs matinale." Acta Medica Scandinavica 95, S90 (April 24, 2009): 73–79. http://dx.doi.org/10.1111/j.0954-6820.1938.tb09017.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Petrukhin, Aleksey. "Pump Insulin Therapy and Continuous Glycemic Monitoring." Spravočnik vrača obŝej praktiki (Journal of Family Medicine), no. 6 (June 1, 2020): 26–32. http://dx.doi.org/10.33920/med-10-2006-03.

Full text

Abstract:

Diabetes mellitus is a chronic disease, which is based on insufficient insulin production, which ultimately leads to the development of hyperglycemia. As a result of the continuous increase in blood sugar levels, many organs and systems suffer, and diabetes is one of the common causes of disability. After the discovery of the true nature of the disease, the main method of treatment is the administration of insulin. The dose and frequency of administration of this drug are selected individually and can be adjusted during treatment. The insulins used at the present stage are represented by ultra-short, short-acting, mediumduration and slow-acting drugs. Ultrashort and short-acting insulins begin to work literally in a few minutes after administration, but the effect persists for a short time. This type of insulin is indicated for subcutaneous administration before meals or immediately after it. Medium and slow-acting insulins are meant to maintain insulin at a certain level for a long time, they are administered at the same time, usually twice a day. Short and ultrashort insulins should be injected into the subcutaneous tissue of the abdomen, while taking into account that the greater the thickness of the subcutaneous fat layer, the slower the absorption. Slow-acting insulins are recommended to be administered to the outer surface of the thigh or buttocks. Insulin is administered using insulin syringes or pen injectors. At present, the use of insulin pumps, which provide continuous supply of insulin using a special device, has become an alternative to the syringe administration of short-acting and ultra-short insulins. Often, such devices are equipped with glucose level sensors, which allows continuous monitoring of blood sugar levels.

APA, Harvard, Vancouver, ISO, and other styles

3

Jayagopal, Vijay, Russell Drummond, and Dinesh Nagi. "Association of British Clinical Diabetologists (ABCD) position statement on the use of biosimilar insulin." British Journal of Diabetes 18, no. 4 (December 12, 2018): 171–74. http://dx.doi.org/10.15277/bjd.2018.190.

Full text

Abstract:

Biosimilar insulins have the potential to offer the NHS a considerable cost saving. The acceptability and use of biosimilar insulin by clinicians and patients may, however, be limited by lack of experience, understanding and concerns about safety and tolerability. This article summarises information on the advantages and disadvantages of using biosimilar insulins and an overview of the published evidence in relation to efficacy, tolerability and safety of current and expected Biosimilar Insulins. The position of the ABCD on the use of Biosimilar Insulin is stated along with the key practical considerations for healthcare staff involved in insulin prescription and administration.

APA, Harvard, Vancouver, ISO, and other styles

4

Andrade, Pedro, Luísa Barros, and Margarida Gonçalo. "Type 1 Ig-E mediated allergy to human insulin, insulin analogues and beta-lactam antibiotics." Anais Brasileiros de Dermatologia 87, no. 6 (December 2012): 917–19. http://dx.doi.org/10.1590/s0365-05962012000600018.

Full text

Abstract:

Insulin, a crucial therapeutic agent for diabetes mellitus, has been rarely associated with hypersensitivity events. We present a 69-year-old type-2 diabetic patient with urticariform lesions on the sites of subcutaneous injection of insulin. The patient denied any known allergies, except for an unspecific cutaneous reaction after intramuscular penicillin administration in childhood. Prick tests revealed positive reactions to all tested human insulins and insulin analogues. Serum IgE levels were above normal range and RAST tests were positive for human, bovine and porcine insulins, as well as beta-lactams. Type 1 IgEmediated allergy to insulin analogues demands a prompt diagnosis and represents a significant therapeutic challenge in diabetic patients.

APA, Harvard, Vancouver, ISO, and other styles

5

Kirchner, K. A. "Insulin increases loop segment chloride reabsorption in the euglycemic rat." American Journal of Physiology-Renal Physiology 255, no. 6 (December 1, 1988): F1206—F1213. http://dx.doi.org/10.1152/ajprenal.1988.255.6.f1206.

Full text

Abstract:

To elucidate the nephron segment(s) responsible for insulin's antinatriuretic effect in the mammalian kidney, late proximal, early distal, and late distal tubule micropuncture was performed during base-line and intravenous insulin infusion in glucose-clamped, volume-expanded rats. During insulin infusion, urinary sodium chloride excretion fell. Blood glucose, arterial pressure, whole kidney and single-nephron inulin clearance, fluid, and chloride delivery out of the proximal convoluted tubule remained unchanged. Early distal chloride delivery decreased (P less than 0.001) during insulin administration. Insulin infusion increased calculated loop chloride reabsorption compared with both base-line values and values for time-control rats. Distal convoluted tubule chloride reabsorption was unchanged during insulin administration. We conclude that 1) euglycemic insulin administration reduces urinary chloride excretion in volume-expanded rats by tubular mechanisms; 2) in superficial nephrons, insulin has no effect on proximal tubule fluid or chloride reabsorption but markedly stimulates chloride reabsorption in the loop; and 3) chloride reabsorption in the distal convoluted tubule was unaltered by insulin administration.

APA, Harvard, Vancouver, ISO, and other styles

6

Taylor, M. Joan, Krishan P. Chauhan, and Tarsem S. Sahota. "Glucose lowering strategies with insulin." British Journal of Diabetes 19, no. 2 (December 17, 2019): 124–30. http://dx.doi.org/10.15277/bjd.2019.228.

Full text

Abstract:

People with type 1 diabetes must use insulin and a large fraction of those with type 2 condition also do so. Many therefore struggle with the unpredictable balancing of insulin dose with calorie intake and utility. A healthy pancreas makes meticulous adjustment on a continuous basis that present therapeutic insulin administration cannot match. However, much progress has been made to make it simpler to inject both background and fast-acting boost insulins with a view to better mimicking normal pancreatic output. The present fast insulins are reviewed with accent on the primary amino acid structures of the biosynthetic types that diffuse more quickly than regular insulin that associates in hexamers. This makes boost doses kinetically and clinically more effective, allowing people to inject better estimated boost and corrective doses. Formulation advances are discussed for their present and potential contributions. The newer slow-acting insulins are also described and compared, their advantage also being kinetic with a lower likelihood of inducing overnight hypoglycaemia when used optimally. Finally, the appreciation of the advantages of alternative routes of administration such as oral and peritoneal are included in this review because of the possibility of altering the hepatic to peripheral ratio, the reasons for which are more effective but less obesogenic insulin activity. The logistics of oral insulin are summarised in terms of the risks to the insulin structure, the facilitation of paracellular uptake at the apical surface and the paradoxically advantageous hepatic first pass. Other non-invasive routes are also included in the review.

APA, Harvard, Vancouver, ISO, and other styles

7

De Meyts, Pierre. "Le récepteur de l’insuline a 50 ans – Revue des progrès accomplis." Biologie Aujourd’hui 216, no. 1-2 (2022): 7–28. http://dx.doi.org/10.1051/jbio/2022007.

Full text

Abstract:

L’isolement de l’insuline du pancréas et sa purification à un degré suffisant pour permettre son administration à des patients atteints de diabète de type 1 furent accomplis il y a 100 ans à l’Université de Toronto par Banting, Best, Collip et McLeod et représentent sans conteste une des plus grandes révolutions thérapeutiques en médecine, reconnue par l’attribution du Prix Nobel de Physiologie ou Médecine en 1923 à Banting et McLeod. Les retombées cliniques furent rapides ainsi que l’internationalisation de sa production commerciale. Les retombées en matière de recherche fondamentale furent beaucoup plus lentes, en particulier en ce qui concerne les mécanismes moléculaires d’action de l’insuline sur ses cellules cibles. Presque un demi-siècle s’écoula avant la détermination de la structure tri-dimensionnelle de l’insuline en 1969 et la caractérisation de son récepteur cellulaire en 1970–1971. Le fait que le récepteur de l’insuline soit une enzyme appelée tyrosine kinase ne fut démontré que dans les années 1982–1985, et la structure cristallographique du domaine kinase intracellulaire fut déterminée dix ans plus tard. La structure cristallographique du premier substrat intracellulaire de la kinase (IRS-1) en 1991 ouvrira la voie à l’élucidation des voies de signalisation intracellulaires. Il faudra 15 ans de plus avant l’obtention de la structure cristallographique du domaine extracellulaire du récepteur (en l’absence d’insuline) en 2006. Depuis, la détermination de la structure du complexe insuline-récepteur dans les états inactif et activé a fait d’énormes progrès, en particulier grâce aux améliorations récentes dans les pouvoirs de résolution de la cryo-microscopie électronique. Je passerai ici en revue les étapes du développement du concept de récepteur hormonal, et de nos connaissances sur la structure et le mécanisme moléculaire d’activation du récepteur de l’insuline.

APA, Harvard, Vancouver, ISO, and other styles

8

Zac-Varghese, Sagen, Bev Summerhayes, and Peter Winocour. "Managing type 1 diabetes in frailty." BMJ Case Reports 15, no. 12 (December 2022): e253779. http://dx.doi.org/10.1136/bcr-2022-253779.

Full text

Abstract:

Managing type 1 diabetes in frail elderly people can be logistically challenging, particularly for those living alone. District nurse visits are unpredictable and coincide poorly with meal time insulin regimes. Elderly people, particularly those with dementia, have variable oral intake and activity. For some, poor glycaemic control leads to frequent and prolonged inpatient admissions. The use of technology, such as flash glucose monitoring, and the use of analogue insulins can be helpful in this setting. Increased monitoring enables more accurate titration of insulin doses and the information can be accessed by healthcare professionals and carers remotely. Longer lasting analogue insulins allow for a greater margin of error in the timing of insulin administration.

APA, Harvard, Vancouver, ISO, and other styles

9

Heinemann, Lutz, and Christopher G. Parkin. "Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice." Journal of Diabetes Research 2018 (2018): 1–9. http://dx.doi.org/10.1155/2018/4568903.

Full text

Abstract:

Despite considerable advances in pharmacotherapy and self-monitoring technologies in the last decades, a large percentage of adults with diabetes remain unsuccessful in achieving optimal glucose due to suboptimal medication adherence. Contributors to suboptimal adherence to insulin treatment include pain, inconvenience, and regimen complexity; however, a key driver is hypoglycemia. Improvements in the PK/PD characteristics of today’s SC insulins provide more physiologic coverage of basal and prandial insulin requirements than regular human insulin; however, they do not achieve the rapid on/rapid off characteristics of endogenously secreted insulin seen in healthy, nondiabetic individuals. Pulmonary administration of prandial insulin represents an attractive option that overcomes limitations of SC insulin by providing more a rapid onset of action and a faster return of action to baseline levels than SC administration of rapid-acting insulin analogs. This article reviews the unique PK/PD properties of a novel inhaled formulation that support its use in patient populations with T1D or T2D.

APA, Harvard, Vancouver, ISO, and other styles

10

Garcia, Joshua, Megan Pintens, Amanda Morris, Paul Takamoto, Laura Baumgartner, and Chelsea L. Tasaka. "Reduced Versus Conventional Dose Insulin for Hyperkalemia Treatment." Journal of Pharmacy Practice 33, no. 3 (September 6, 2018): 262–66. http://dx.doi.org/10.1177/0897190018799220.

Full text

Abstract:

Background: Using a reduced dose of 5 units of regular insulin has been proposed as a strategy to mitigate the risk of hypoglycemia when treating hyperkalemia. The comparative efficacy and safety of this strategy to conventional 10 units is not well established. Objective: To compare the effectiveness of reduced and conventional dosed insulin for hyperkalemia treatment. Methods: Electronic medication administration reports of conventional or reduced doses of insulin given for hyperkalemia treatment were reviewed from July 2013 to September 2015. The primary outcome was reduction in serum potassium. Results: Ninety-two administrations of reduced dose insulin and 309 administrations of conventional dose insulin were included. No significant difference was found in potassium reduction between the groups (−0.096 mmol/L, P value = .2210). Post hoc subgroup analysis of patients with serum potassium > 6 mmol/L revealed a lower reduction in potassium in the reduced dose group compared to the conventional dose group (difference: −0.238 mmol/L, P value = .018). Conclusions Conventional dose insulin may be more effective than reduced dose regular insulin at baseline serum potassium levels >6 mmol/L in the treatment of hyperkalemia. Frequent monitoring of serum potassium and glucose after administration of insulin is necessary to confirm adequate response and avoidance of hypoglycemia.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Insuline – Administration"

1

Rollin, Bénédicte. "Les stylos injecteurs d'insuline : enquête auprès des diabétiques utilisateurs." Paris 5, 1990. http://www.theses.fr/1990PA05P237.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Guillat, Corinne. "Place du stylo à insuline dans le traitement du diabète sucré." Montpellier 1, 1991. http://www.theses.fr/1991MON11114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Saslawski, Olivier. "Systèmes à libération pulsée d'insuline à partir de matrices polymériques hydrophiles (système magnétique, système thermique)." Paris 11, 1990. http://www.theses.fr/1990PA114811.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Stahl, Olivier. "Le stylo injecteur d'insuline, comparaison avec les autres systèmes d'aministration insulinique." Strasbourg 1, 1991. http://www.theses.fr/1991STR15083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Callet, Adeline. "Administration orale d'insuline par double encapsulation : développement du système nanoparticulaire par coacervation complexe insuline/chitosane." Strasbourg, 2010. https://publication-theses.unistra.fr/public/theses_doctorat/2010/CALLET_Adeline_2010.pdf.

Full text

Abstract:

Le diabète est une maladie chronique qui touche plus de 3 millions de personnes en France. Se traduisant par une perte du contrôle de la glycémie, son traitement actuel par injections pluri-quotidiennes d’insuline entraîne un inconfort des patients. D’autres voies d’administrations ont été développées, comme la voie orale qui constitue la voie d’administration la plus physiologique, la plus confortable et la mieux acceptée par le patient. Néanmoins, des contraintes physico-chimiques peuvent entraîner une perte de l’activité hypoglycémiante de l’insuline. Afin de la protéger et de permettre son administration orale, un vecteur pharmaceutique complexe a été élaboré par double encapsulation : un véhicule apportant une protection gastrique et des nanoparticules apportant une protection intestinale. L’insuline ainsi encapsulée au sein de ces nanoparticules est protégée du milieu intestinal et peut alors franchir la barrière intestinale pour rejoindre la circulation sanguine afin d’être libérée. Ces nanoparticules sont obtenues par coacervation complexe avec le chitosane, polymère naturel bioassimilable. Néanmoins, celui-ci présente une solubilité limitée à pH physiologique rendant difficile sa complexation avec l’insuline. Deux dérivés du chitosane ont été utilisés : un dérivé obtenu par modifications chimiques, le N-,O-carboxyméthyl chitosane (NOCC) et un sel de chitosane, le chitosane chlorhydrate. Une caractérisation approfondie de ces deux dérivés hydrosolubles du chitosane permet d’envisager la complexation de l’insuline à pH physiologique. L’étude de la complexation est réalisée dans le cas de ces deux dérivés. L’obtention de diagrammes de turbidité permet de définir la zone de formation des nanoparticules. Celles-ci présentent une taille moyenne comprise entre 300 et 500 nm, une charge positive (+ 40 mV) et contiennent en moyenne 85 à 90 % d’insuline encapsulée. Des études in vitro ont permis de montrer leur stabilité en milieu intestinal. Leurs propriétés biologiques ont été vérifiées à l’aide de manipulations in vivo sur des rats diabétiques. Ces essais ont montré la conservation de l’activité biologique de l’insuline et la capacité des nanoparticules à induire une diminution de la glycémie pouvant conduire à l’obtention de la normoglycémie, 8 heures après leur administration. Les nanoparticules obtenues à l’aide des deux dérivés hydrosolubles du chitosane protègent l’insuline (conservation de son activité biologique) du milieu intestinal et lui permettent de traverser la barrière intestinale. Ces résultats permettent la validation du concept d’encapsulation d’insuline par coacervation complexe. Les nanoparticules peuvent désormais faire partie intégrante du vecteur pharmaceutique complexe afin d’être administrées par voie orale
Diabetes mellitus is a chronic disease which affects more than 3 millions people in France. Translated by a loss of glycaemia control, its current treated by daily insulin injections entailing discomfort of patients. Other administrations way have been developed and the oral route constitute the most physiological, comfortable and best accepted by patients. Nevertheless, physico-chemical constraints can lead to lose hypoglyceamiant activity of insulin. To avoid it, a pharmaceutical complex vector was developed by double encapsulation: a vehicle bringing a gastric protection and nanoparticles bringing an intestinal protection. By this way, encapsulated insulin in nanoparticles is protected from the intestinal environment and can then cross intestinal barrier to join the blood circulation to be released. These nanoparticles were obtained by complex coacervation with chitosan, a natural and biocompatible polymer. Nevertheless, its low solubility at physiological pH makes its complexation with insulin difficult. Two different water-soluble chitosan derivatives were formed: one obtained by chemical modifications, N-, O-carboxymethyl chitosan (NOCC) and one chitosan salt, chitosan chlorhydrate. A detailed characterization of these two water-soluble derivatives allows insulin complexation at physiological pH. A complexation study made for these two compounds allows the definition of a complexation area where nanoparticles were formed. They had shown average size from 300 to 500 nm, positive charge (+40 mV) and encapsulation efficiency of 85-90 %. In vitro studies allowed to show nanoparticles stability as well as intestinal resistance. Their biological properties were verified by in vivo experiments on diabetic rats, showing the conservation of insulin biological activity and ability to induce glycaemia decrease going to normoglycaemia in 8 hours. Nanoparticles obtained with two water-soluble chitosan derivatives, protect insulin (conservation of biological activity) from the intestinal environment and allow it to cross intestinal barrier. These results permit the validation of insulin encapsulation by complex coacervation concept. Hence nanoparticles can be included in the complex pharmaceutical vector to be administered by oral way

APA, Harvard, Vancouver, ISO, and other styles

6

LAMBOLEZ, ANNE-MARIE. "Evolution des formes galeniques et mode d'administration de l'insuline." Strasbourg 1, 1989. http://www.theses.fr/1989STR15029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Marambat, Isabelle. "Réaction œdémateuse à la mise en route d'une thérapie insulinique." Bordeaux 2, 1989. http://www.theses.fr/1989BOR25132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Diop, Mouhamadou. "Formulation, développement et validation de systèmes particulaires d'insuline en vue de leur administration par voie orale." Thesis, Strasbourg, 2015. http://www.theses.fr/2015STRAJ081/document.

Full text

Abstract:

Administration par voie orale.L’insulinothérapie permet aux diabétiques de réguler leur glycémie. La thèse s’inscrit dans le projet ORAIL Bis qui vise à développer un système d’administration orale d’insuline basé sur la double encapsulation de l’insuline. Le vecteur développé est composé d’une gélule contenant des particules (NP) d’insuline formulées à partir de chitosane (CS) par coacervation complexe ou d’acide (lactique-co-glycolique) (PLGA) par double émulsion. Les objectifs de la thèse sont de stabiliser les NP de chitosane par réticulation et lyophilisation, augmenter la biodisponibilité des NP de PLGA par mucoadhésion, les transposer à l’échelle industrielle. Les résultats ont montré que la combinaison des deux approches permet de réduire la taille des NP de CS, de maintenir une charge positive, de leur conférer une stabilité et une bioefficacité. La mucoadhésion n’a pas permis d’augmenter la biodisponibilité des NP de PLGA. Une charge négative permet d’améliorer leur efficacité biologique et sont transposable à échelle industrielle. L’encapsulation de ces NP dans une gélule a permis de valider in vivo le concept de double encapsulation de l’insuline
Insulinotherapy helps diabetics to regulate their glycaemia. This thesis is part of the ORAIL Bis project which aims to develop an oral insulin delivery system based on the double encapsulation of insulin. The developed vector is composed of a capsule containing insulin loaded particles (NPs) formulated with chitosan (CS) by complex coacervation or poly (lactic-co-glycolic) acid (PLGA) by double emulsion solvent evaporation. The objectives of the thesis are to stabilize chitosan NPs by crosslinking and freeze-drying, increase the bioavailability of NPs PLGA by mucoadhesion and transpose them to the industrial scale. Results showed that the combination of both strategies reduces the size of CS NPs, maintain a positive charge, give them stability and bioefficacy. Mucoadhesion failed to increase the bioavailability of PLGA NPs. A negative charge allows to improve their biological efficacy and are transposed to industrial scale. The encapsulation of these NPs in an alginate capsule allowed to validate in vivo the concept of double encapsulation of insulin

APA, Harvard, Vancouver, ISO, and other styles

9

ABOUBAKAR, MALAM. "Nanocapsules de poly(isobutylcyanoacrylate) chargees en insuline : contribution a la comprehension du mecanisme d'action apres administration orale (doctorat : pharmacotechnie et biopharmacie)." Paris 11, 1999. http://www.theses.fr/1999PA114829.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Reix, Nathalie. "Administration orale d'insuline : validation in vitro et in vivo d'un système basé sur une double encapsulation de l'insuline." Strasbourg, 2009. http://www.theses.fr/2009STRA2495.

Full text

Abstract:

Le but de ce travail a été de valider in vitro et in vivo une formulation d’insuline administrable par voie orale. Afin de permettre à l’insuline de franchir les barrières chimiques gastrointestinales (pH, enzymes) et physiques (épithélium intestinal), nous avons développé un système de double encapsulation. La première encapsulation permettant le passage de la barrière intestinale est réalisé à partir d’acide poly(lactique-co-glycolique) afin d’obtenir des nanoparticules par la méthode de double émulsion eau/huile/eau. La seconde encapsulation a consisté à intégrer ces nanoparticules dans une gélule gastrorésistante enrobée d’Eudragit® L100-55. Les nanoparticules (NP) synthétisées ont une taille moyenne de 165 ±4nm et un taux d’encapsulation de l’insuline de 95%. La toxicité a été évaluée par un test de viabilité sur une lignée de cellules intestinales, les Caco-2, en utilisant des concentrations de nanoparticules de 0 à 80 mg de PLGA/mL /cm2. Une toxicité apparaît mais à des doses supraphysiologiques. L’absorption des nanoparticules par les Caco-2 a été quantifiée par cytométrie en flux et visualisée par microscopie confocale. Il a été ainsi démontré que l’absorption des nanoparticules se fait selon un mécanisme clathrine-dépendant. Des rats diabétiques (STZ) ont reçu des NP par gavage sans qu’il y ait d’effet sur la glycémie, ce qui atteste que ces NP ne sont pas gastrorésistants, d’où la nécessité de la gélule entérique. Les administrations d’insuline en solution, faites par voie intraduodénale, n’ont aucun effet sur la glycémie, en revanche, l’insuline encapsulée administrée de la même façon induit une normoglycémie au bout de 8h. La biofonctionnalité intestinale des NP a été évaluée en administrant de l’insuline par voie intrapéritonéale et de l’insuline encapsulée par voie intraduodénale à des rats diabétiques et la biodisponibilité après administration par ces mêmes voies de peptide-C. La biofonctionnalité est d’au moins 20% et la biodisponibilité de 6,3%. La lyophilisation et le compactage des nanoparticules ont permis de les inclure dans les gélules entériques et de débuter des tests de glycémie après administration orale. Les procédures de synthèse utilisées permettent d’obtenir des NP absorbables par un épithélium intestinal in vitro et qui sont biofonctionnelles après administration intraduodénale. Cette nouvelle formulation de l’insuline semble être une approche prometteuse pour l’administration d’insuline administrable par voie orale
The purpose of this study was to develop a new formulation of oral insulin. Normally, peptide hormones like insulin are given by parenteral injections routes because they are destroyed by the acid and proteolytic enzymes in stomach and intestine. Our project focuses on insulin double encapsulation for oral administration. The first system of encapsulation of insulin is based on Poly(Lactide-co-Glycolide) Acid (PLGA) nanoparticles. This should allow the uptake and the transport across mucosal intestinal barrier. These nanoparticles are put in a gastroresistant capsule made of Eudragit® L100-55. After synthesis, the size of nanoparticles is 165 ±4 nm and the rate of encapsulation is around 95%. In vitro, the absorption has been quantify by flow cytometry and visualized by confocal microscopy. A clathrin dependant endocytosis pathway mechanism has been demonstrated. In vivo, the biofunctionnality of the nanoparticles was evaluated after subcutaneous injections. After nanoparticles gastric force feeding no effect was seen on the glycemia because nanoparticles are not gastroresistant. We measured the kinetic of the glycemia and the biofunctionnality of NP in streptozotocin-induced diabetic rats after intra-duodenal injections of insulin nanoparticles and intraperitoneal injections of insulin. The bioavaibility was evaluated after quantification of the C-peptidemia after intra-peritoneal injections of C-peptide and after intraduodenal injections of the same quantity of encapsulated C-peptide. Intraduodenal injections of insulin nanoparticles induce a significant decrease of glycemia 8h after injection. In comparison with intra-peritoneal injections, results showed that nanoparticles’ biofunctionnality is at less 20% and the biodisponibility is 6,3%. PLGA insulin-loaded nanoparticles are efficient and the biological effect of insulin is preserved. These polymeric particles allow the absorption of insulin through intestinal mucosa into the bloodstream. Thus this new delivery insulin formulation seems to be an interesting approach

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Insuline – Administration"

1

United States. Food and Drug Administration. Office of Women's Health. Insulin. Washington, D.C.]: Dept. of Health and Human Services, FDA, Office of Women's Health, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Human insulin: Clinical pharmacological studies in normal man. Lancaster: MTP Press, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Tattersall, Robert. Diabetes, a practical guide for patients on insulin. 2nd ed. Edinburgh: Churchill Livingstone, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Fisher, Simon Jeremy. Use of the matched step tracer infusion procedure to evaluate the effects of different routes of insulin administration and to compare the effects of insulin and insulin-like growth factor I. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Registered Nurses' Association of Ontario., ed. Best practice guideline for the subcutaneous administration of insulin in adults with type 2 diabetes. Toronto: Registered Nurses Association of Ontario = L'association des infirmières et infirmiers autorisés de l'Ontario, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Havas, Stephen. Self-control: A physician's guide to blood glucose monitoring in the management of diabetes. Leawood, KS: American Academy of Family Physicians, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Page, Brackenridge Betty. Diabetes 101: A pure and simple guide for people who use insulin. 3rd ed. Minneapolis, MN: Chronimed Pub., 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Heller, Richard F. The carbohydrate addict's healthy heart program: Break your carbo-insulin connection to heart disease. New York: Ballantine Pub. Group, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Page, Brackenridge Betty. Diabetes 101: Candy apples, log cabins & you : a pure and simple guide for people who use insulin. 2nd ed. Minneapolis, MN: Chronimed Pub., 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Melvin, Wiedman, ed. Diabetes: Current research and future directions in management and cure. Jefferson, N.C: McFarland, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Insuline – Administration"

1

Strachan, Mark W. J., and Brian M. Frier. "Subcutaneous Insulin Administration." In Insulin Therapy, 17–27. London: Springer London, 2013. http://dx.doi.org/10.1007/978-1-4471-4760-2_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Li, Mo-Yi, Hong Peng, Min-Rong Ai, Hui-Bi Xu, and You-Shang Zhang. "Sublingual administration of monomeric insulin— destetrapeptide insulin." In Peptides Biology and Chemistry, 249–51. Dordrecht: Springer Netherlands, 2002. http://dx.doi.org/10.1007/0-306-46880-8_62.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Matthews, D. R. "Insulin: The physiological basis of its administration." In Pathogenesis and Treatment of Diabetes Mellitus, 131–41. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4301-8_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rasmussen, Christian Hove, Tue Søeborg, Erik Mosekilde, and Morten Colding-Jørgensen. "Absorption Kinetics of Insulin Mixtures after Subcutaneous Administration." In Biosimulation in Biomedical Research, Health Care and Drug Development, 329–59. Vienna: Springer Vienna, 2011. http://dx.doi.org/10.1007/978-3-7091-0418-7_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Horwitz, David L., and David C. Klonoff. "New Technologies for Glucose Monitoring and Insulin Administration." In Textbook of Diabetes, 414–25. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118924853.ch30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Saffran, Murray. "Oral Administration of Insulin: Imitating the Natural Pathway." In Targeting of Drugs 3, 89–95. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-2938-5_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wolpert, Howard, and Judy Shih. "New Technologies for Insulin Administration and Glucose Monitoring." In Textbook of Diabetes, 440–51. Oxford, UK: Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9781444324808.ch28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Vora, J. P., and D. R. Owens. "Future trends in insulin therapy: clinical implications of novel insulin analogues and nasal administration of insulin." In Pharmacology of Diabetes, edited by C. E. Mogensen and E. Standl, 39–56. Berlin, Boston: De Gruyter, 1990. http://dx.doi.org/10.1515/9783110850321-006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Dogan, Ahmet, and Oana Madalina Mereuta. "Iatrogenic Pharmaceutical Amyloidosis Associated with Insulin and Enfuvirtide Administration." In Current Clinical Pathology, 481–85. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-19294-9_35.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Colette, Claude, Louis Monnier, Jacques Arnal, Jean-Louis Selam, and Jacques Mirouze. "Effects of Different Insulin Administration Modalities on Vitamin D Metabolism of Insulin-Dependent Diabetic Patients." In Phosphate and Mineral Homeostasis, 501–8. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-5206-8_62.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Insuline – Administration"

1

Moreno, A., J. P. de la Cruz, J. Garcia Campos, and F. Sanchez de la Cuesta. "EFFECT OF DIPYRIDAMOLE + ASA ON THE RETINE VASCULAR PATTERN OF ESTREPTOZOTOCIN-DIABETIC RATS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643098.

Full text

Abstract:

INTRODUCTIONWe have used an experimental model which allows the evaluation of the qualitative differences in the retinal vascular pattern by means of the labeling of the retine vascular tree with radish peroxidase (HRP) in estreptozotocin-diabetic rats. The aim of the study was to evaluate the effect of ASA and DIP + ASA on the vessels platelet behaviour of said retine pattern in a group of rats in t-hich the diabetes had 3 months of evolution.PROCEDURE22 Wistar male rats were divided into A groups; 1) control group, 2) diabetic rats without antiaggregant, 3) dietetic rats treated with 6 mg/day ASA p.o., 4) diabetic rats treated with 6 mg/day ASA +12 mg/day DIP p.o. For inducing diabetes 30 mg/Kg of i.v. estreptozotocine were administered. The animals were considered “diabetic” when glucemia was over 200 mg/100 ml. After 3 months of treatment with 4IU insuline and ASA, or ASA + DIP, the animals were sacrified. Samples of blood and rings of descending aorta were extracted. Platelet aggregation in IJB in front of 1 μg/ml of collagen and the prostacycline-like activity of the aorta ring were evaluated. The configuration of the retine vascular tree labeled with HRP was observed.RESULTS AND CONCLUSIONSMaximal aggregation intensity: 11.1 Ω in the control group,10.9Ω in the diabetic non-treated group, 4.8Ω in rats receiving ASA and 4.6Ω in rats treated with DIP + ASA. The incUbation during 10 min. of aorta rings in blood samples produced 38.7% inhibition in the control group, 12.8% in the non treated-diabetic group 0% in the ASA group and 49.3% in the group treated with DIP + ASA.The qualitative changes in the diabetic rats retinal vascular network non treated with antiaggregants showed a scarce visibility of capillars as well as large zones of tortuous vessels. The rats treated with ASA showed a continuous vascular bed and less tortuous vessels than the ones in the non treated group but the vascular diameters were smaller than the ones observed in non-diabetic rats; the rats treated with DIP + ASA showed a continuous vascular bed, scarce tortuous vessels and vascular diameters similar to the ones found in non-diabetic rats. Mortality rates: 0% in the control group, 50% in the non-treated diabetic group, 16% in the ASA group and 0% in the DIP + ASA group. The administration of DIP + ASA normalized the prostacycline-like activity and the retinal vascular pattern in estreptozotocin-diabetic rats.

APA, Harvard, Vancouver, ISO, and other styles

2

Goyal, S., and C. Bidder. "G155(P) Insulin: Time it right. Timing of insulin administration in relation to a meal is as important as its administration." In Royal College of Paediatrics and Child Health, Abstracts of the Annual Conference, 24–26 May 2017, ICC, Birmingham. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2017. http://dx.doi.org/10.1136/archdischild-2017-313087.154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ramya, S., S. Praveen Kumar, S. Padhma Vinodhini, D. Lingaraja, and G. Dinesh Ram. "Design of MEMS based Micro-Pumps Transdermal Insulin Administration." In 2023 Second International Conference on Electronics and Renewable Systems (ICEARS). IEEE, 2023. http://dx.doi.org/10.1109/icears56392.2023.10085422.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Urzeala, Constanta, and Mihaela Vlaiculescu. "TELEMEDICINE AND PHYSICAL EXERCISE FOR THE CHILD WITH DIABETES." In eLSE 2016. Carol I National Defence University Publishing House, 2016. http://dx.doi.org/10.12753/2066-026x-16-241.

Full text

Abstract:

This paper is a case study that highlights our concern for increasing the quality of life of the child with diabetes, using telemedicine devices. The central objective is to emphasize the efficiency of the Omnipod wireless insulin pump in the case of a child who, together with the diabetes care team, appropriately manages this metabolic disease and whose treatment also includes physical exercise. Our interest is oriented towards proving the effects derived from the practice of physical exercises on decreasing the amount of insulin administered during the days when the child participates in motor activities, through computerized monitoring. The research was conducted at the Bucharest DiabNutriMed Clinic of Diabetes, from September to November 2015. As research methods, we used: bibliographic study, observation, case study. Data were collected using the computerized DEXCOM Platinum G4 continuous glucose monitoring devices, the Omnipod wireless insulin pump and their related software programs, and the Diasend platform for downloading the data. We present the case of a child with diabetes who has been using a wireless insulin pump since June 2015. We mention that this child is included in the target group of the project sponsored by Vodafone, "Telemedicine and the insulin-dependent child", obtained by the DiabNutriMed Clinic,which aims to introduce advanced technology, with sensors for continuous glucose monitoring, 24hours a day, which eliminates the need for daily injections to measure the glucose levels. During our study, the child participated regularly in physical exercise programs, three times a week, outside the school schedule, practicing activities such as swimming and dynamic games. Information about the child's glucose level and its evolution trend was sent to a web platform and visualized in real time by the family and the diabetes physician, who provided guidance on treatment. According to the indications, the family could remotely administer insulin using the wireless insulin pump with remote control, while the child was carrying out educational and recreational activities uninterruptedly. It was found that, during the days of participation in motor activities, the amount of insulin decreased, its administration being even suspended when the child showed a tendency towards persistent hypoglycemia, which is impossible to achieve in the insulin therapy administered with an insulin pen, where, once administered, insulin cannot be stopped any more over its entire duration of action, 4 to 6 hours (for rapid insulin). Recording these beneficial effects of physical exercises on the child with diabetes entitles us to state that the Omnipod wireless insulin pump represents not only an instrument for insulin administration, but also a possibility of individualized management adaptable to the activities of the child from minute to minute, which allows him/her free access to various activities. In conclusion, we consider as efficient the use of telemedicine devices for the child with diabetes, because it facilitates a good control of this disease and brings more hope in his life.

APA, Harvard, Vancouver, ISO, and other styles

5

"Intelligent Drug/Dosage Decision & Administration Using R-Pi SBC An Intravenous Pre-Operative Insulin Administration Scenario." In Dec. 14-16, 2016 Pattaya. Dignified Researchers Publication, 2016. http://dx.doi.org/10.15242/dirpub.dir1216015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Aldali, Sara Haitham, and Sownd Sankaralingam. "Induction of Glyoxalase 1 to prevent Methylglyoxal-Induced Insulin Resistance in Cardiomyocytes." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0230.

Full text

Abstract:

Background: Type 2 Diabetes mellitus is characterized by hyperglycemia and insulin resistance. Methylglyoxal (MG) a highly reactive dicarbonyl compound is also increased in diabetes. MG is detoxified by glyoxalase 1 (Glo-1) enzyme using reduced glutathione (GSH) as a co-factor. MG has been shown to have deleterious effects on cardiovascular cells and impairs insulin signaling. Insulin resistance is associated with diabetic cardiomyopathy. Trans-resveratrol (tRES) and Hesperetin (HES) combination has been shown to increase Glo-1 and improve insulin signaling in obese patients. Aim(s): The aim of this study is to investigate whether tRES-HES combination prevents MG-induced cardiac insulin resistance and the underlying mechanisms in cardiomyocytes in culture. Methodology: (H9C2) rat cardiomyocytes were treated with MG (100 µM) for 24 hours in the presence or absence of tRES-HES (10 µM). Glo-1 activity was determined by the formation of S-D lactoylglutathione; protein expression of P-Akt and P-GSK3b was determined using Western blot. In some experiments, cells were stimulated with insulin (100 nM) for 10 minutes to test insulin sensitivity. Results: MG reduced Glo-1 activity by ~25%, blunted insulin-induced phosphorylation of Akt and Gsk3b and increased the expression of beta-myosin heavy chain by ~50% (a marker of cardiac dysfunction) significantly (P˂0.05) compared to untreated control group of cells. Co-administration of tRES-HES combination restored Glo1 activity, maintained insulin-induced phosphorylation of Akt and GSK3b and prevented the increase in beta myosin heavy chain significantly (P<0.05). Conclusion: Induction of Glo1 prevents MG-induced cardiac insulin resistance and the increase in marker of cardiac dysfunction. This strategy could be helpful in preventing cardiovascular complications associated with diabetes.

APA, Harvard, Vancouver, ISO, and other styles

7

Arpaia, Pasquale, Davide Cuneo, Francesca Mancino, and Nicola Moccaldi. "A Bioimpedance-based Transducer for Insulin Bioavailability Assessment after Subcutaneous Administration." In 2022 IEEE International Instrumentation and Measurement Technology Conference (I2MTC). IEEE, 2022. http://dx.doi.org/10.1109/i2mtc48687.2022.9806567.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ambrosiadou, B. V., M. Alevizos, and G. Ziakas. "Decision support in diabetes management for optimal glycaemic control by insulin administration." In Proceedings of IEEE Systems Man and Cybernetics Conference - SMC. IEEE, 1993. http://dx.doi.org/10.1109/icsmc.1993.390883.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Chbat, N. W., and T. K. Roy. "Glycemic Control in Critically Ill Patients Effect of Delay in Insulin Administration." In 2005 IEEE Engineering in Medicine and Biology 27th Annual Conference. IEEE, 2005. http://dx.doi.org/10.1109/iembs.2005.1616978.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kirchsteiger, Harald, Luigi del Re, Eric Renard, and Margot Mayrhofer. "Robustness properties of optimal insulin bolus administrations for Type 1 diabetes." In 2009 American Control Conference. IEEE, 2009. http://dx.doi.org/10.1109/acc.2009.5160729.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Insuline – Administration"

1

Boisclair, Yves R., and Arieh Gertler. Development and Use of Leptin Receptor Antagonists to Increase Appetite and Adaptive Metabolism in Ruminants. United States Department of Agriculture, January 2012. http://dx.doi.org/10.32747/2012.7697120.bard.

Full text

Abstract:

Objectives The original project had 2 major objectives: (1) To determine the effects of centrally administered leptin antagonist on appetite and adaptive metabolism in the sheep; (2) To develop and prepare second-generation leptin antagonists combining high binding affinity and prolonged in vivo half-life. Background Periods of suboptimal nutrition or exaggerated metabolic activity demands lead to a state of chronic energy insufficiency. Ruminants remain productive for a surprisingly long period of time under these circumstances by evoking adaptations sparing available energy and nutrients. The mechanism driving these adaptations in ruminant remains unknown, but could involve a reduction in plasma leptin, a hormone acting predominantly in the brain. In laboratory animals, reduced leptin signaling promotes survival during nutritional insufficiency by triggering energy sparing adaptations such as reduced thyroid hormone production and insulin resistance. Our overall hypothesis is that similar adaptations are triggered by reduced leptin signaling in the brain of ruminants. Testing of this hypothesis in ruminants has not been possible due to inability to block the actions of endogenous leptin and access to ruminant models where leptin antagonistic therapy is feasible and effective. Major achievements and conclusions The Israeli team had previously mutated 3 residues in ovine leptin, with no effect on receptor binding. This mutant was renamed ovine leptin antagonist (OLA) because it cannot activate signaling and therefore antagonizes the ability of wild type leptin to activate its receptor. To transform OLA into an effective in vivo antagonist, the Israeli made 2 important technical advances. First, it incorporated an additional mutation into OLA, increasing its binding affinity and thus transforming it into a super ovine leptin antagonist (SOLA). Second, the Israeli team developed a method whereby polyethylene glycol is covalently attached to SOLA (PEG-SOLA) with the goal of extending its half-life in vivo. The US team used OLA and PEG-SOLA in 2 separate animal models. First, OLA was chronically administered directly into the brain of mature sheep via a cannula implanted into the 3rdcerebroventricule. Unexpectedly, OLA had no effect of voluntary feed intake or various indicators of peripheral insulin action but reduced the plasma concentration of thyroid hormones. Second, the US team tested the effect of peripheral PEG-SOLA administration in an energy sensitive, rapidly growing lamb model. PEG-SOLA was administered for 14 consecutive days after birth or for 5 consecutive days before sacrifice on day 40 of life. Plasma PEG-SOLA had a half-life of over 16 h and circulated in 225- to 288-fold excess over endogenous leptin. PEG-SOLA administration reduced plasma thyroid hormones and resulted in a higher fat content in the carcass at slaughter, but had no effects on feed intake, body weight, plasma glucose or insulin. These results show that the team succeeded in developing a leptin antagonist with a long in vivo half-life. Moreover, in vivo results show that reduced leptin signaling promotes energy sparing in ruminants by repressing thyroid hormone production. Scientific and agricultural implications The physiological role of leptin in ruminants has been difficult to resolve because peripheral administration of wild type leptin causes little effects. Our work with leptin antagonists show for the first time in ruminants that reduced leptin signaling induces energy sparing mechanisms involving thyroid hormone production with little effect on peripheral insulin action. Additional work is needed to develop even more potent leptin antagonists, to establish optimal administration protocols and to narrow down phases of the ruminant life cycle when their use will improve productivity.

APA, Harvard, Vancouver, ISO, and other styles

2

Funkenstein, Bruria, and Shaojun (Jim) Du. Interactions Between the GH-IGF axis and Myostatin in Regulating Muscle Growth in Sparus aurata. United States Department of Agriculture, March 2009. http://dx.doi.org/10.32747/2009.7696530.bard.

Full text

Abstract:

Growth rate of cultured fish from hatching to commercial size is a major factor in the success of aquaculture. The normal stimulus for muscle growth in growing fish is not well understood and understanding the regulation of muscle growth in fish is of particular importance for aquaculture. Fish meat constitutes mostly of skeletal muscles and provides high value proteins in most people's diet. Unlike mammals, fish continue to grow throughout their lives, although the size fish attain, as adults, is species specific. Evidence indicates that muscle growth is regulated positively and negatively by a variety of growth and transcription factors that control both muscle cell proliferation and differentiation. In particular, growth hormone (GH), fibroblast growth factors (FGFs), insulin-like growth factors (IGFs) and transforming growth factor-13 (TGF-13) play critical roles in myogenesis during animal growth. An important advance in our understanding of muscle growth was provided by the recent discovery of the crucial functions of myostatin (MSTN) in controlling muscle growth. MSTN is a member of the TGF-13 superfamily and functions as a negative regulator of skeletal muscle growth in mammals. Studies in mammals also provided evidence for possible interactions between GH, IGFs, MSTN and the musclespecific transcription factor My oD with regards to muscle development and growth. The goal of our project was to try to clarify the role of MSTNs in Sparus aurata muscle growth and in particular determine the possible interaction between the GH-IGFaxis and MSTN in regulating muscle growth in fish. The steps to achieve this goal included: i) Determining possible relationship between changes in the expression of growth-related genes, MSTN and MyoD in muscle from slow and fast growing sea bream progeny of full-sib families and that of growth rate; ii) Testing the possible effect of over-expressing GH, IGF-I and IGF-Il on the expression of MSTN and MyoD in skeletal muscle both in vivo and in vitro; iii) Studying the regulation of the two S. aurata MSTN promoters and investigating the possible role of MyoD in this regulation. The major findings of our research can be summarized as follows: 1) Two MSTN promoters (saMSTN-1 and saMSTN-2) were isolated and characterized from S. aurata and were found to direct reporter gene activity in A204 cells. Studies were initiated to decipher the regulation of fish MSTN expression in vitro using the cloned promoters; 2) The gene coding for saMSTN-2 was cloned. Both the promoter and the first intron were found to be polymorphic. The first intron zygosity appears to be associated with growth rate; 3) Full length cDNA coding for S. aurata growth differentiation factor-l I (GDF-II), a closely related growth factor to MSTN, was cloned from S. aurata brain, and the mature peptide (C-terminal) was found to be highly conserved throughout evolution. GDF-II transcript was detected by RT -PCR analysis throughout development in S. aurata embryos and larvae, suggesting that this mRNA is the product of the embryonic genome. Transcripts for GDF-Il were detected by RT-PCR in brain, eye and spleen with highest level found in brain; 4) A novel member of the TGF-Bsuperfamily was partially cloned from S. aurata. It is highly homologous to an unidentified protein (TGF-B-like) from Tetraodon nigroviridisand is expressed in various tissues, including muscle; 5) Recombinant S. aurata GH was produced in bacteria, refolded and purified and was used in in vitro and in vivo experiments. Generally, the results of gene expression in response to GH administration in vivo depended on the nutritional state (starvation or feeding) and the time at which the fish were sacrificed after GH administration. In vitro, recombinantsaGH activated signal transduction in two fish cell lines: RTHI49 and SAFI; 6) A fibroblastic-like cell line from S. aurata (SAF-I) was characterized for its gene expression and was found to be a suitable experimental system for studies on GH-IGF and MSTN interactions; 7) The gene of the muscle-specific transcription factor Myogenin was cloned from S. aurata, its expression and promoter activity were characterized; 8) Three genes important to myofibrillogenesis were cloned from zebrafish: SmyDl, Hsp90al and skNAC. Our data suggests the existence of an interaction between the GH-IGFaxis and MSTN. This project yielded a great number of experimental tools, both DNA constructs and in vitro systems that will enable further studies on the regulation of MSTN expression and on the interactions between members of the GHIGFaxis and MSTN in regulating muscle growth in S. aurata.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!